release date：2026-01-30
2026 WHX Labs Dubai | Feb 10–13, Dubai World Trade Centre. Discover TargetingOne’s D-Series fully automated digital PCR systems at Booth SA.G09. We warmly welcome your visit and insightful exchanges.
D-Series Automatic Digital PCR system on display
The TargetingOne D20/D30 fully automated digital PCR system is the "star product" at this exhibition. It integrates droplet generation, PCR amplification, and droplet detection into one
Ultra-multiplex Molecular Solutions
TargetingOne will prominently showcase ultra-multiplex detection overall solutions—including for lung cancer, thyroid cancer, sepsis, and NIPT—developed based on the D-Series fully automated digital PCR platform. These products precisely cover three major disease diagnosis and treatment fields: oncology, infectious diseases, and birth defects.
Exhibition Background and Market Opportunities
Formerly MEDLAB Middle East, this exhibition has grown over 25 years to become a global benchmark in laboratory diagnostics. It recorded an outstanding business turnover of USD 720 million in 2025. As a key Middle Eastern trading hub, Dubai offers unrivalled access to global markets. With its heavy dependence on imported lab equipment and favorable free trade policies, it unlocks enormous market potential for Chinese medical companies. For TargetingOne, this event is an ideal platform to demonstrate our cutting-edge technologies, deepen global partnerships, and expand into international markets together. We warmly welcome clients, experts, scholars and industry colleagues to our booth for valuable discussions and interactions.
● About TargetingOne ●
TargetingOne was founded in 2015 and is headquartered in Zhongguancun Science Park. As a national high-tech enterprise and a Beijing-certified "Specialized, Refined, Distinctive, and Innovative" SME, the company focuses on independent innovation in life sciences and molecular diagnostics. It boasts a high-caliber R&D team with expertise in instruments, chips, materials, reagents, and software. The company has experienced rapid growth, filing over 200 patents globally and securing more than 150 authorized patents. It consistently publishes academic papers in authoritative journals and undertakes national-level research grants.Based on its proprietary digital PCR technology, TargetingOne has obtained the first and second NMPA Class III Medical Device Registration Certificates for digital PCR systems (totaling three certificates), as well as three NMPA Class III Medical Device Registration Certificates for diagnostic reagents. Among these, its reagents for infection and solid tumor liquid biopsy were the first digital PCR diagnostic reagents to receive Class III registration in China. The company has twice been awarded the Gold Prize for Outstanding Innovative IVD Products in China, won the championship in the Zhongguancun International Frontier Technology Innovation Competition, and received the Beijing Science and Technology Award (Second Class) and the Invention Entrepreneurship Achievement Award.Additionally, its self-developed open molecular POCT integrated system and rapid qPCR testing reagents have both obtained NMPA Class III Medical Device Registration Certificates. Adhering to the philosophy of "Innovation Makes Precision Accessible," TargetingOne is committed to developing advanced technologies that are multiplex, high-throughput, automated, contamination-resistant, and cost-effective. It aims to become a leading enterprise in life sciences and molecular diagnostics, serving the fields of life science research, precision medicine, drug development, and health management.